Chris Abell
From Wikipedia, the free encyclopedia
Chris Abell, MA, PhD (born 11 November 1957) is a British biological chemist. He is a professor in Biological Chemistry in the Department of Chemistry of the University of Cambridge and Todd-Hamied Fellow of Christ's College.
His research interests include vitamin and amino acid biosynthesis as targets for the rational design of antimicrobials and antiparasitics; fragment-based approaches to enzyme inhibition; bacterial and plant riboswitches; reactions in microdroplets; and biological nanotechnology.
His awards include an ICI Prize in Organic Chemistry in 1992.
Abell is the co-founder of two companies: Astex Technology Ltd, which uses fragment-based drug discovery technology to discover cancer therapeutics, and Akubio, which develops biosensors for detecting bacteria and viruses.
[edit] Selected publications
Bulloch EM, Jones MA, Parker EJ, Osborne AP, Stephens E, Davies GM, Coggins JR, Abell C (2004) Identification of 4-amino-4-deoxychorismate synthase as the molecular target for the antimicrobial action of (6S)-6-fluoroshikimate J Am Chem Soc 126, 9912–9913
Bruckbauer A, Zhou D, Kang DJ, Korchev YE, Abell C, Klenerman D (2004) An addressable antibody nanoarray produced on a nanofabricated surface J Am Chem Soc 126, 6508–6509
Webb ME, Stephens E, Smith AG, Abell C (2003) Rapid screening by MALDI-TOF mass spectrometry to probe binding specificity at enzyme active sites Chem Commun Oct 7, 2416–2417
Blundell TL, Jhoti H, Abell C (2002) High throughput crystallography for lead discovery in drug design Nat Rev Drug Discov 2002, 1, 45–54
[edit] External links
- Abell group home page (University of Cambridge)
- Bridging the gap between protein chemistry and organic synthesis, Chem@Cam, 2004
 This article about a British scientist is a stub. You can help Wikipedia by expanding it. |
